REPORT FROM THE 2009 AAN ANNUAL MEETING – Early progression of disability, a high relapse rate and ongoing MRI activity appear to be indicators of an inadequate response to disease-modifying therapy, according to the 15-year follow-up results of the MS Collaborative Study Group pivotal trial of beta-interferon-1a (Avonex) (Bermel et al. AAN 2009; abstract P02.117).